Program
Hyaluronoglucosaminidase
Also written as “HYQVIA”, “HyQvia” and “hyaluronidase”.
Its studies are mostly in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Primary Immunodeficiency Diseases · Hypersensitivity, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 60 open or running | phase 4since Apr 12, 2017 | Sep 11, 2015 | none ahead |
| Amphastar Pharmaceuticals | 10 open or running | phase 2since Sep 13, 2012 | Sep 13, 2012 | none ahead |
| Baxter Healthcare | 10 open or running | phase 1since Jun 26, 2007 | Jun 26, 2007 | none ahead |
| Shanghai Bao Pharmaceuticals | 10 open or running | phase 3since Sep 12, 2024 | Sep 12, 2024 | none ahead |
Also a collaborator on its studies: Takeda Development Center Americas, Baxalta Innovations GmbH, now part of Shire and Halozyme Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 26, 2007First study: phase 1 study in HealthyNew to Baxter HealthcareBaxter Healthcare · NCT00493220 · 30 enrolled
- Sep 13, 2012Amphastar Pharmaceuticals’ first study: phase 2 study in HypersensitivityNew to Amphastar PharmaceuticalsAmphastar Pharmaceuticals · NCT01689363 · 253 enrolled · United States
- Sep 11, 2015Takeda’s first study: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNew to TakedaTakeda · NCT02549170 · 138 enrolled · United States, Argentina, Brazil and more
- Nov 2, 2016Phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingTakeda · NCT02955355 · 85 enrolled · United States, Argentina, Brazil and more
- Apr 12, 2017Phase 4 study in Primary Immunodeficiency DiseasesTakeda · NCT03116347 · 42 enrolled · Czechia, Denmark, France and more
- Sep 7, 2017Phase 3 study in Primary Immunodeficiency DiseasesTakeda · NCT03277313 · 44 enrolled · United States
- Jul 7, 2020Phase 1 study in Healthy VolunteersTakeda · NCT04578535 · 51 enrolled · United States
- Sep 12, 2024Shanghai Bao Pharmaceuticals’ first study: phase 3 study in HealthyNew to Shanghai Bao PharmaceuticalsShanghai Bao Pharmaceuticals · NCT06604546 · 45 enrolled · China
- Mar 20, 2025Phase 1 study in Healthy VolunteersTakeda · NCT06895967 · 30 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06895967Healthy Volunteers · United States | 1 | Completed | Takeda | Jul 24, 2025 | 30 |
| NCT06604546Healthy · China | 3 | Completed | Shanghai Bao Pharmaceuticals | May 5, 2024 | 45 |
| NCT04578535Healthy Volunteers · United States | 1 | Completed | Takeda | Mar 2, 2022 | 51 |
| NCT03277313Primary Immunodeficiency Diseases · United States | 3 | Completed | Takeda | Jul 20, 2022 | 44 |
| NCT03116347Primary Immunodeficiency Diseases · Czechia, Denmark, France and more | 4 | Completed | Takeda | Jan 15, 2021 | 42 |
| NCT02955355Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Brazil and more | 3 | Completed | Takeda | Jul 4, 2023 | 85 |
| NCT02549170Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Brazil and more | 3 | Completed | Takeda | Feb 23, 2022 | 138 |
| NCT01689363Hypersensitivity · United States | 2 | Completed | Amphastar Pharmaceuticals | Nov 2012 | 253 |
| NCT00493220Healthy | 1 | Completed | Baxter Healthcare | Sep 2007 | 30 |
How it is read
Names in the registry
- “HYQVIA”, 10 entries
- “HyQvia”, 1 entry
- “hyaluronidase”, 1 entry
- “Hyaluronidase”, 1 entry
- “SC HYLENEX and Ceftriaxone”, 1 entry
Conditions, from the studies’ own filings
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 2 studies
- Primary Immunodeficiency Diseases, 2 studies
- Hypersensitivity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.